ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Q: What does CUSIP 82835W108 represent in this 13F holders report?

CUSIP 82835W108 is the security identifier for SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in Q2 2022?

60 institutional investors reported SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share for Q2 2022. Use the holders table for investor-level position and value details.

CUSIP: 82835W108

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 98,600,500
Total 13F shares: 26,061,019
Share change: -769,580
Total reported value: $110,514,000
Put/Call ratio: 203%
Price per share: $4.24
Number of holders: 60
Value change: -$387,734
Number of buys: 36
Number of sells: 42

Quarterly Holders Quick Answers

What is CUSIP 82835W108?
CUSIP 82835W108 identifies SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 82835W108:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	8.9%	8,740,887	$30,681,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	3.8%	3,793,041	$13,314,000	—	31 Mar 2022	13F
WASATCH ADVISORS LP	13F	Company	3%	2,974,228	$10,440,000	—	31 Mar 2022	13F
Nextech Invest Ltd.	13F	Company	1.9%	1,910,029	$6,704,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	1.6%	1,607,500	$5,642,000	—	31 Mar 2022	13F
Nantahala Capital Management, LLC	13F	Company	0.93%	913,597	$3,152,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	0.83%	823,296	$2,890,000	—	31 Mar 2022	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.68%	670,542	$2,354,000	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.41%	401,176	$1,408,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.39%	385,947	$1,355,000	—	31 Mar 2022	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.38%	370,800	$1,302,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.37%	362,640	$1,272,000	—	31 Mar 2022	13F
Ensign Peak Advisors, Inc	13F	Company	0.35%	346,024	$1,215,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	0.35%	344,194	$1,208,000	—	31 Mar 2022	13F
EcoR1 Capital, LLC	13F	Company	0.33%	329,537	$1,157,000	—	31 Mar 2022	13F
Prosight Management, LP	13F	Company	0.33%	325,365	$1,142,000	—	31 Mar 2022	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.3%	300,574	$1,055,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.27%	263,761	$926,000	—	31 Mar 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.2%	195,156	$685,000	—	31 Mar 2022	13F
D. E. Shaw & Co., Inc.	13F	Company	0.19%	187,322	$658,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.18%	173,569	$609,000	—	31 Mar 2022	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	0.15%	151,608	$534,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.15%	147,375	$518,000	—	31 Mar 2022	13F
IndexIQ Advisors LLC	13F	Company	0.12%	113,499	$398,000	—	31 Mar 2022	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.1%	102,700	$360,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.1%	101,691	$357,000	—	31 Mar 2022	13F
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	13F	Company	0.1%	95,897	$337,000	—	31 Mar 2022	13F
Janney Montgomery Scott LLC	13F	Company	0.09%	84,566	$297,000	—	31 Mar 2022	13F
Woodline Partners LP	13F	Company	0.08%	83,571	$293,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.07%	64,723	$272,000	—	31 Mar 2022	13F
Jonathan Piazza	3/4/5	Chief Financial Officer	— mixed-class rows	156,608 mixed-class rows	$261,878	—	02 May 2022	3/4/5
Valerie Odegard	3/4/5	President and CSO	— mixed-class rows	152,106 mixed-class rows	$233,180	—	02 May 2022	3/4/5
Bank of New York Mellon Corp	13F	Company	0.06%	58,554	$206,000	—	31 Mar 2022	13F
Naomi Hunder	3/4/5	Chief Medical Officer	— mixed-class rows	140,782 mixed-class rows	$205,897	—	02 May 2022	3/4/5
Allspring Global Investments Holdings, LLC	13F	Company	0.04%	40,601	$142,000	—	31 Mar 2022	13F
Russ Hawkinson	3/4/5	Sr. Vice President of Finance	— mixed-class rows	93,921 mixed-class rows	$140,921	—	02 May 2022	3/4/5
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.04%	39,720	$139,000	—	31 Mar 2022	13F
OCCUDO QUANTITATIVE STRATEGIES LP	13F	Company	0.04%	36,331	$128,000	—	31 Mar 2022	13F
Cubist Systematic Strategies, LLC	13F	Company	0.04%	36,281	$127,000	—	31 Mar 2022	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.03%	34,000	$119,000	—	31 Mar 2022	13F
Avantax Planning Partners, Inc.	13F	Company	0.03%	32,174	$113,000	—	31 Mar 2022	13F
BAILARD, INC.	13F	Company	0.03%	30,265	$106,000	—	31 Mar 2022	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.03%	28,500	$100,000	—	31 Mar 2022	13F
RHUMBLINE ADVISERS	13F	Company	0.02%	24,075	$85,000	—	31 Mar 2022	13F
APOGEM CAPITAL LLC	13F	Company	0.02%	23,969	$84,000	—	31 Mar 2022	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.02%	22,894	$80,000	—	31 Mar 2022	13F
XTX Topco Ltd	13F	Company	0.02%	22,137	$78,000	—	31 Mar 2022	13F
PARAMETRIC PORTFOLIO ASSOCIATES LLC	13F	Company	0.02%	21,759	$76,000	—	31 Mar 2022	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	19,803	$70,000	—	31 Mar 2022	13F
BARCLAYS PLC	13F	Company	0.02%	17,105	$60,000	—	31 Mar 2022	13F

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q2 2022

As of 30 Jun 2022, ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) was held by 60 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 26,061,019 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, Nextech Invest AG, K2 PRINCIPAL FUND, L.P., Nantahala Capital Management, LLC, VANGUARD GROUP INC, Rubric Capital Management LP, BlackRock Inc., EcoR1 Capital, LLC, and RENAISSANCE TECHNOLOGIES LLC. This page lists 60 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Q2 2022 holders

Holder diff

-6

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.